New York, USA, July 20, 2022 (GLOBE NEWSWIRE) — The Global Immunohistochemistry Market to Surge at a CAGR of 7.64% by 2027 | DelveInsight
The immunohistochemistry market is anticipated to grow due to the rise in cases of chronic and infectious diseases such as cancer, and herpes virus infection, among others, and the rising implementation of automation and machine learning concepts in the field of IHC are the factors expected to spur the immunohistochemistry market in the upcoming years.
DelveInsight’s Immunohistochemistry Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, immunohistochemistry market drivers, barriers, and trends, and key immunohistochemistry companies in the market.
Key Takeaways from the Immunohistochemistry Market Report
- As per DelveInsight analysis, North America is anticipated to dominate the global immunohistochemistry market during the forecast period.
- Leading immunohistochemistry companies such as Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, PerkinElmer Inc., Danaher Corporation, Merck KGaA, Bio-Techne., Genemed Biotechnologies, Inc., Abcam plc, Becton, Dickinson and Company, Bio SB, Inc., BioGenex., Biocare Medical, LLC., Diagnostic BioSystems Inc., ROCKLAND IMMUNOCHEMICALS, INC., Elabscience Biotechnology Inc., Sakura Finetek USA, Inc., CANDOR Bioscience GmbH,…
